Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Karen Lingnau"'
Autor:
Attila Szabo, Peter Gogolak, Kitti Pazmandi, Katalin Kis-Toth, Karin Riedl, Benjamin Wizel, Karen Lingnau, Attila Bacsi, Bence Rethi, Eva Rajnavolgyi
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e55264 (2013)
The aim of this study was to characterize and identify the mode of action of IC31®, a two-component vaccine adjuvant. We found that IC31® was accumulated in human peripheral blood monocytes, MHC class II positive cells and monocyte-derived DCs (moD
Externí odkaz:
https://doaj.org/article/9dbe321337934cf3b936c18e5564d108
Autor:
Attila Szabo, Peter Gogolak, Kitti Pazmandi, Katalin Kis-Toth, Karin Riedl, Benjamin Wizel, Karen Lingnau, Attila Bacsi, Bence Rethi, Eva Rajnavolgyi
Publikováno v:
PLoS ONE, Vol 8, Iss 10 (2013)
Externí odkaz:
https://doaj.org/article/844c7c3b08f4440e817398059c4ed2df
Autor:
Laura Pattacini, Gregory J Mize, Jessica B Graham, Tayler R Fluharty, Tisha M Graham, Karen Lingnau, Benjamin Wizel, Beatriz Perdiguero, Mariano Esteban, Giuseppe Pantaleo, Mingchao Shen, Gregory A Spies, M Juliana McElrath, Jennifer M Lund
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e42163 (2012)
The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regimen using a canarypox vector and an HIV envelope protein with alum, as shown in the RV144 trial. Since the efficacy was weak, and previous HIV vaccine
Externí odkaz:
https://doaj.org/article/b71871af8b57400e809b877fadc0013c
Autor:
Arun T Kamath, Anne-Françoise Rochat, Mario P Valenti, Else Marie Agger, Karen Lingnau, Peter Andersen, Paul-Henri Lambert, Claire-Anne Siegrist
Publikováno v:
PLoS ONE, Vol 3, Iss 11, p e3683 (2008)
BACKGROUND: With the exception of some live vaccines, e.g. BCG, subunit vaccines formulated with "classical" adjuvants do not induce similar responses in neonates as in adults. The usual neonatal profile is characterized by lower levels of TH1-associ
Externí odkaz:
https://doaj.org/article/17c59911479c4944a8b06fa054424fb4
Autor:
Nina V, Wressnigg, Romana, Hochreiter, Martina, Schneider, Michaela J, Obersriebnig, Nicole I, Bézay, Karen, Lingnau, Irena Čorbić, Ramljak, Katrin L, Dubischar, Susanne, Eder-Lingelbach
Publikováno v:
Journal of Travel Medicine.
Background Zika virus (ZIKV) is an emerging public health threat, rendering development of a safe and effective vaccine against the virus a high priority to face this unmet medical need. Our vaccine candidate has been developed on the same platform u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::085f9f7e2f5fedb5e40c50a8d592c1fd
https://doi.org/10.1093/jtm/taac127
https://doi.org/10.1093/jtm/taac127
Autor:
Martina Schneider, Karen Lingnau, Nina Wressnigg, Julian Larcher-Senn, Irena Čorbic-Ramljak, Katrin L. Dubischar, Romana Hochreiter, Urban Lundberg, Susanne Eder-Lingelbach, Andrea Fritzer, Nicole Bézay, Wolfgang Bender, Oliver Zoihsl, Anton Klingler, Andreas Meinke
Publikováno v:
The Lancet. Infectious diseases. 20(10)
Summary Background Chikungunya disease, which results in incapacitating arthralgia, has been reported worldwide. We developed a live-attenuated chikungunya virus (CHIKV) vaccine candidate designed for active immunisation of the general population liv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3377852a6e320f38dbca6c28f45619b
https://pubmed.ncbi.nlm.nih.gov/32497525
https://pubmed.ncbi.nlm.nih.gov/32497525
Autor:
Martina Schneider, Oliver Zoihsl, Andreas Pilz, Susanne Eder-Lingelbach, Anton Klingler, Katrin L. Dubischar, Wolfgang Bender, Nina Wressnigg, Andreas Meinke, Romana Hochreiter, Urban Lundberg, Karen Lingnau, Nicole Bézay, Andrea Fritzer
Publikováno v:
SSRN Electronic Journal.
Background: Chikungunya disease has been reported worldwide resulting in incapacitating arthralgia. We developed a live-attenuated Chikungunya virus vaccine candidate designed for active immunization of the general population living in endemic region
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7153e9049f955432629291b83d534b34
https://doi.org/10.2139/ssrn.3463306
https://doi.org/10.2139/ssrn.3463306
Autor:
Karen Lingnau, Veronika Sexl, Ulrich Kalinke, Alexander von Gabain, Wolfgang Kratky, Thomas Rülicke, Thomas Kolbe, Mathias Müller, Andreas Pilz, Dagmar Stoiber, Olivia Simma, Silvia Stockinger, Thomas Decker
Publikováno v:
The Journal of Immunology. 183:2286-2293
Phosphorylation of transcription factor STAT-1 on Y701 regulates subcellular localization whereas phosphorylation of the transactivating domain at S727 enhances transcriptional activity. In this study, we investigate the impact of STAT-1 and the impo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3da260b1838c7f3f0db9383740fbfb0
https://doi.org/10.4049/jimmunol.0901383
https://doi.org/10.4049/jimmunol.0901383
Publikováno v:
Scandinavian Journal of Immunology. 69:194-202
IC31 is a novel adjuvant which combines the immunostimulatory effects of an 11-mer antibacterial peptide (KLKL(5)KLK) and a synthetic oligodeoxynucleotide (ODN1a) which is a Toll-like receptor 9 agonist without containing cytosine phosphate guanine (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4cf195c7364a95b377ffb2e361fcb1f
https://doi.org/10.1111/j.1365-3083.2008.02225.x
https://doi.org/10.1111/j.1365-3083.2008.02225.x
Publikováno v:
Vaccine. 26:3461-3468
The compromised immune responses in the elderly as well as the threat of pandemic influenza necessitate the development of improved influenza vaccines. This study provides evidence that IC31 ® , a two-component synthetic adjuvant signalling through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bfca2628bdc25d4aff992120fdfa5e2
https://doi.org/10.1016/j.vaccine.2008.04.029
https://doi.org/10.1016/j.vaccine.2008.04.029